When assessing percentage change of the absolute number we confirmed that not progressing MS patients showed a marker reduction of CD3+CD20+ lymphocytes from month 6 thereafter, a slight naïve regulatory T cells reduction from month 6 thereafter and a marked reduction in memory regulatory B cells from month 3 thereafter with no differences among progressing and non-progressing patients for CD8+ T lymphocytes, CD4/CD8 ratio and natural killer (Supplementary Table 3). This evidence concerns the gene CD4 and myeloid sarcoma.